Cardiotoxicity: Importance of biomarkers
Kardiotoksičnost: Važnost biomarkera
Authors
Kostadinović, JelenaPopadić, Višeslav
Klašnja, Slobodan
Klisić, Aleksandra

Kotur-Stevuljević, Jelena

Andrić, Zoran
Zdravković, Marija
Article (Published version)
Metadata
Show full item recordAbstract
The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant
diseases, usually has certain limitations due to its cardiotoxicity (CT) and consequent
cardiomyopathy, or even heart failure. CT
is defined as any cardiac injury connected with
oncology treatment, whether it is chemo
-, radio
-, targeted or immunotherapy, or cancer by itself,
and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors
related t
o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method
of application, combination with other cardiotoxic drugs or association with radiotherapy) and
patient characteristics (age, presence of cardiovascular risk factors, pr
evious cardiovascular
disease) are the determining factors that influence the frequency of CT. Imaging methods for
morphological and functional monitoring of the ... heart muscle are used for monitoring CT. The
quest for diagnostic tools for early CT detection
is of great significance. In line with this, the
measurement of some cardiac biomarkers has found its place in clinical settings as an early
determinant of myocardial injury. Therefore, in this review article, special attention will be paid
to certain wel
l-established, as well as certain novel cardiac biomarkers, and their role in
recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility.
Klinička efikasnost hemioterapije, kao priznatog terapeutskog pristupa malignim
bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične
kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda
povezana s lečenjem raka, uzimajući u obzir hemioterapiju, radioterapiju, biološku ili
imunoterapiju, kao i sam karcinom, te predstavlja veliki izazov za kliničare
u svakodnevnoj
praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa,
kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili
povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog
rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za
praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića.
Potraga za dij
agnostič...kim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim,
merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto
u kliničkim okruženjima. Stoga
će u ovom preglednom članku posebna pažnja biti po
sve
ć
ena
nekim dobro utvrđenim, kao i nekim novim srčanim biomarkerima, i njihovoj ulozi u
prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost
i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.
Keywords:
cardiotoxicity biomarkers / anthracyclines / trastuzumab / biomarkeri kardiotoksičnosti / antraciklini / trastuzumabSource:
Arhiv za farmaciju, 2023, 73, 1-16Publisher:
- Savez farmaceutskih udruženja Srbije (SFUS)
Collections
Institution/Community
PharmacyTY - JOUR AU - Kostadinović, Jelena AU - Popadić, Višeslav AU - Klašnja, Slobodan AU - Klisić, Aleksandra AU - Kotur-Stevuljević, Jelena AU - Andrić, Zoran AU - Zdravković, Marija PY - 2023 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4629 AB - The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant diseases, usually has certain limitations due to its cardiotoxicity (CT) and consequent cardiomyopathy, or even heart failure. CT is defined as any cardiac injury connected with oncology treatment, whether it is chemo -, radio -, targeted or immunotherapy, or cancer by itself, and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors related t o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method of application, combination with other cardiotoxic drugs or association with radiotherapy) and patient characteristics (age, presence of cardiovascular risk factors, pr evious cardiovascular disease) are the determining factors that influence the frequency of CT. Imaging methods for morphological and functional monitoring of the heart muscle are used for monitoring CT. The quest for diagnostic tools for early CT detection is of great significance. In line with this, the measurement of some cardiac biomarkers has found its place in clinical settings as an early determinant of myocardial injury. Therefore, in this review article, special attention will be paid to certain wel l-established, as well as certain novel cardiac biomarkers, and their role in recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility. AB - Klinička efikasnost hemioterapije, kao priznatog terapeutskog pristupa malignim bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda povezana s lečenjem raka, uzimajući u obzir hemioterapiju, radioterapiju, biološku ili imunoterapiju, kao i sam karcinom, te predstavlja veliki izazov za kliničare u svakodnevnoj praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa, kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića. Potraga za dij agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim, merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto u kliničkim okruženjima. Stoga će u ovom preglednom članku posebna pažnja biti po sve ć ena nekim dobro utvrđenim, kao i nekim novim srčanim biomarkerima, i njihovoj ulozi u prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost i neželjene efekte lekova koji se primenjuju u terapiji karcinoma. PB - Savez farmaceutskih udruženja Srbije (SFUS) T2 - Arhiv za farmaciju T1 - Cardiotoxicity: Importance of biomarkers T1 - Kardiotoksičnost: Važnost biomarkera VL - 73 SP - 1 EP - 16 DO - 10.5937/arhfarm73-40534 ER -
@article{ author = "Kostadinović, Jelena and Popadić, Višeslav and Klašnja, Slobodan and Klisić, Aleksandra and Kotur-Stevuljević, Jelena and Andrić, Zoran and Zdravković, Marija", year = "2023", abstract = "The clinical efficacy of chemotherapy, as a recognized therapeutic approach for malignant diseases, usually has certain limitations due to its cardiotoxicity (CT) and consequent cardiomyopathy, or even heart failure. CT is defined as any cardiac injury connected with oncology treatment, whether it is chemo -, radio -, targeted or immunotherapy, or cancer by itself, and it represents a great challenge for clinicians in everyday practice. A wide spectrum of factors related t o chemotherapy (type of drug, dose during each cycle, cumulative dose, schedule, method of application, combination with other cardiotoxic drugs or association with radiotherapy) and patient characteristics (age, presence of cardiovascular risk factors, pr evious cardiovascular disease) are the determining factors that influence the frequency of CT. Imaging methods for morphological and functional monitoring of the heart muscle are used for monitoring CT. The quest for diagnostic tools for early CT detection is of great significance. In line with this, the measurement of some cardiac biomarkers has found its place in clinical settings as an early determinant of myocardial injury. Therefore, in this review article, special attention will be paid to certain wel l-established, as well as certain novel cardiac biomarkers, and their role in recognizing asymptomatic CT, in order to gain deeper insight into their diagnostic utility., Klinička efikasnost hemioterapije, kao priznatog terapeutskog pristupa malignim bolestima, obično ima određena ograničenja zbog svoje kardiotoksičnosti (KT), te posledične kardiomiopatije, pa čak i srčane insuficijencije. KT se definiše kao svaka povreda miokarda povezana s lečenjem raka, uzimajući u obzir hemioterapiju, radioterapiju, biološku ili imunoterapiju, kao i sam karcinom, te predstavlja veliki izazov za kliničare u svakodnevnoj praksi. Širok spektar faktora povezanih s hemioterapijom (vrsta leka, doza tokom svakog ciklusa, kumulativna doza, raspored, način primene, kombinacija s drugim kardiotoksičnim lekovima ili povezanost s radioterapijom) i karakteristike bolesnika (dob, prisutnost faktora kardiovaskularnog rizika, prethodne kardiovaskularne bolesti), odlučujući su faktori koji utiču na učestalost KT. Za praćenje KT koriste se radiološke metode za morfološko i funkcionalno praćenje srčanog mišića. Potraga za dij agnostičkim alatima za rano otkrivanje KT od velikog je značaja. U skladu s tim, merenje nekih srčanih biomarkera kao rane determinante povrede miokarda našlo je svoje mesto u kliničkim okruženjima. Stoga će u ovom preglednom članku posebna pažnja biti po sve ć ena nekim dobro utvrđenim, kao i nekim novim srčanim biomarkerima, i njihovoj ulozi u prepoznavanju asimptomatske KT, kako bi se stekao dublji uvid u njihovu dijagnostičku korisnost i neželjene efekte lekova koji se primenjuju u terapiji karcinoma.", publisher = "Savez farmaceutskih udruženja Srbije (SFUS)", journal = "Arhiv za farmaciju", title = "Cardiotoxicity: Importance of biomarkers, Kardiotoksičnost: Važnost biomarkera", volume = "73", pages = "1-16", doi = "10.5937/arhfarm73-40534" }
Kostadinović, J., Popadić, V., Klašnja, S., Klisić, A., Kotur-Stevuljević, J., Andrić, Z.,& Zdravković, M.. (2023). Cardiotoxicity: Importance of biomarkers. in Arhiv za farmaciju Savez farmaceutskih udruženja Srbije (SFUS)., 73, 1-16. https://doi.org/10.5937/arhfarm73-40534
Kostadinović J, Popadić V, Klašnja S, Klisić A, Kotur-Stevuljević J, Andrić Z, Zdravković M. Cardiotoxicity: Importance of biomarkers. in Arhiv za farmaciju. 2023;73:1-16. doi:10.5937/arhfarm73-40534 .
Kostadinović, Jelena, Popadić, Višeslav, Klašnja, Slobodan, Klisić, Aleksandra, Kotur-Stevuljević, Jelena, Andrić, Zoran, Zdravković, Marija, "Cardiotoxicity: Importance of biomarkers" in Arhiv za farmaciju, 73 (2023):1-16, https://doi.org/10.5937/arhfarm73-40534 . .